Professor Clare Scott, an internationally recognised expert in gynaecological cancer research, is Laboratory Head, Walter and Eliza Hall Institute of Medical Research and Chair of Gynaecological Cancer, University of Melbourne. A clinician-scientist, her research into susceptibility and resistance to precision therapies for rare cancers, particularly rare ovarian cancers, has resulted in pivotal contributions to the development of the landscape-changing, PARP inhibitor treatment. With conspicuous clinical trial leadership and the development of an internationally renowned resource of pre-clinical models, Professor Scott has also developed innovative national infrastructure, enabling access for Australians with rare cancers to expert clinical advice and research.